HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Filing of New Patent Application

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office for the use of its DehydraTECH™ technology to improve the speed and quantity of absorption of active pharmaceutical ingredients through the skin. This update comes on the heels of Lexaria’s recently detailed successful laboratory evaluation of DehydraTECH™ in the transdermal delivery of cannabidiol. Per company data, the platform demonstrated as much as a 225 percent increase in CBD permeability when compared to control formulations featuring leading commercial penetration enhancers, as well as a nearly 1,900 percent increase in CBD permeability when compared to a control formulation that was devoid of any commercial penetration enhancer. This new patent application includes protection for the delivery of all of the active ingredient classes identified in Lexaria’s other issued and pending patent applications, including cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and phosphodiesterase inhibitors.

To view the full press release, visit http://cnw.fm/k1OZX

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

More from CannabisNewsBreaks

• HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model
• HempNewsBreaks – CannabisNewsWire Named Official Newswire of 2025 Cannabis Means Business Expo in NYC 
• HempNewsBreaks – Turning Point Brands Inc. (NYSE: TPB) Closes $300M Senior Secured Notes Offering 

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net